WO2000066174A2 - Compounds - Google Patents
Compounds Download PDFInfo
- Publication number
- WO2000066174A2 WO2000066174A2 PCT/IE2000/000041 IE0000041W WO0066174A2 WO 2000066174 A2 WO2000066174 A2 WO 2000066174A2 IE 0000041 W IE0000041 W IE 0000041W WO 0066174 A2 WO0066174 A2 WO 0066174A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ranitidine
- adduct
- clarithromycin
- hydrate
- base
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title description 5
- 229960000620 ranitidine Drugs 0.000 claims abstract description 28
- 229960002626 clarithromycin Drugs 0.000 claims abstract description 22
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 208000018522 Gastrointestinal disease Diseases 0.000 claims abstract description 6
- 238000009472 formulation Methods 0.000 claims abstract description 5
- VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- 239000003125 aqueous solvent Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 abstract 2
- 239000000047 product Substances 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 206010019375 Helicobacter infections Diseases 0.000 description 2
- 241000191938 Micrococcus luteus Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- XAUTYMZTJWXZHZ-IGUOPLJTSA-K bismuth;(e)-1-n'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-n-methyl-2-nitroethene-1,1-diamine;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 XAUTYMZTJWXZHZ-IGUOPLJTSA-K 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229960004696 ranitidine bismuth citrate Drugs 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 208000028861 Helicobacter pylori infectious disease Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000001622 bismuth compounds Chemical class 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- -1 carbapenems Chemical class 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- Ranitidine is a H 2 -receptor antagonist of formula (I):
- a combination therapy comprising Ranitidine and antibacterial agents is also generally accepted.
- the activity of Ranitidine, especially against Helicobacter organisms, can be significantly increased by co-administration of antibiotics.
- antibiotics are suitable for this purpose, e.g. tetracyclines, penicillins, carbapenems, cephalosporins, aminoglycosides or macrolide antibiotics. Clarithromycin appears to show in combination with Ranitidine higher eradication rates regarding Helicobacter infections than any other antibiotic
- European patent application EP 533 281 describes the use of Ranitidine bismuth citrate in combination with various types of antibiotics for the treatment or prevention of gastrointestinal disorders.
- the individual components may be co- administered in separate or single compositions.
- One of the problems with combined therapies is one of patient compliance, especially when different quantities or numbers of the individual elements are to be administered.
- This invention is directed towards providing a novel presentation for such combination products which will overcome at least some of these problems.
- the invention provides novel pharmaceutically active and stable adducts containing Clarithromycin and Ranitidine or a hydrate thereof wherein the molar ratio of Clarithromycin to Ranitidine in the adduct is at least 2:1.
- the preferred H 2 -receptor antagonist is Ranitidine which is preferably introduced as the base hydrate.
- the ratios may be integers or non-integers.
- the invention also provides a process for the preparation of an adduct of the invention in which Clarithromycin and Ranitidine are reacted in an organic or aqueous solvent.
- the reaction temperature is from 20°C to 25°C.
- the solvent is petroleum ether.
- the invention further provides the use of the adducts of the invention for the treatment of gastrointestinal disorders.
- the invention provides a pharmaceutical formulation including an adduct of the invention. Detailed description of the invention
- the Ranitidine can be administered simultaneously with the Clarithromycin in one unit.
- the ratio of Ranitidine to Clarithromycin can be readily varied, as required.
- the formed adducts may be readily used for final product formulations, e.g. for the manufacture of tablets or capsules. No pre-mixing of the individual components is required.
- Ranitidine is especially suitable to form adducts with Clarithromycin. Ranitidine may be used conveniently as the base without converting it into a pharmaceutically acceptable and stable salt prior to the formation of the adduct.
- Ranitidine may be reacted with Clarithromycin to produce novel adducts which are of high stability.
- the adducts are antibiotically active and suitable for the treatment of gastiointestinal disorders.
- Adducts prepared from Ranitidine base hydrate and Clarithromycin were found to be of particular interest.
- Ranitidine base hydrate is described in detail in our WO-A-99/65890 the entire contents of which are incorporated herein by reference.
- Such adducts can be obtained via a very simple process in high quality and quantitative yield under very mild reaction conditions.
- novel adducts may be conveniently formulated, e.g. preferably into orally administerable medicaments such as tablets or capsules.
- medicaments such as tablets or capsules.
- Those skilled in the art can decide which excipients, carriers, solvents, fillers, lubricants, techniques and quantities are employed in the formulation process.
- the invention will be more clearly understood from the following example.
- Powder X-ray peaks of medium and high intensity Powder X-ray peaks of medium and high intensity:
- Clarithromycin-Ranitidine [2:1]: 2 ⁇ 8.81, 9.75, 11.04, 11.68, 13.98, 15.35, 16.69, 17.06, 17.45, 18.27, 19.27, 20.04, 20.67, 22.36 ( Figure 2).
- Micrococcus luteus from stock was streaked on a nutrient agar plate to confirm colony morpbiology, colour and purity. After 24 hours incubation at 37°C an isolated colony is picked and inoculated into 10 ml of nutrient broth. This is incubated overnight at 37°C and is subsequently used as the inoculum.
- Quantitation of activity is determined using an MIC (Mean Inhibitory Concentration) liquid tube assay.
- concentrations are set up: 10 ⁇ g/ml, 5 ⁇ g/ml, 1 ⁇ g/ml, 0.5 ⁇ g/ml, 0J ⁇ g/ml, 0.05 ⁇ g/ml and 0.01 ⁇ g/ml.
- concentrations are set up: 10 ⁇ g/ml, 5 ⁇ g/ml, 1 ⁇ g/ml, 0.5 ⁇ g/ml, 0J ⁇ g/ml, 0.05 ⁇ g/ml and 0.01 ⁇ g/ml.
- the tubes were incubated at 37°C and observed for growth after 24 hours and 48 hours. Growth is assessed by dense turbidity, optical density at 660 nm using a spectrophotometer or clarity. The MIC is the last concentration where growth inhibited.
- Clarithromycin-Ranitidine [2:1] ⁇ 0.01 Ranitidine Base Hydrate no significant antibiotic activity
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An adduct contains Clarithromycin and Ranitidine either in the form of a base or a base hydrate in which the molar ratio of Clarithromycin to Ranitidine in the adduct is at least 2:1. The adduct has high stability and is particularly useful in a single dose formulation for the treatment of gastrointestinal disorders.
Description
"COMPOUNDS"
Introduction
Ranitidine is a H2-receptor antagonist of formula (I):
It inhibits the gastric acid secretion and is widely used in the treatment of gastrointestinal disorders. For the eradication of Helicobacter pylori infections, which are closely related to peptic ulcer diseases, bismuth compounds such as Ranitidine bismuth citrate are commonly administered.
A combination therapy comprising Ranitidine and antibacterial agents is also generally accepted. The activity of Ranitidine, especially against Helicobacter organisms, can be significantly increased by co-administration of antibiotics. A variety of antibiotics are suitable for this purpose, e.g. tetracyclines, penicillins, carbapenems, cephalosporins, aminoglycosides or macrolide antibiotics. Clarithromycin appears to show in combination with Ranitidine higher eradication rates regarding Helicobacter infections than any other antibiotic
(Arzneim.-Forsch. 45(2), 184-186 [1995]).
European patent application EP 533 281 describes the use of Ranitidine bismuth citrate in combination with various types of antibiotics for the treatment or prevention of gastrointestinal disorders. The individual components may be co- administered in separate or single compositions.
While such combination products are useful, it is generally difficult to provide such combination products in acceptable formulations. One of the problems with
combined therapies is one of patient compliance, especially when different quantities or numbers of the individual elements are to be administered.
This invention is directed towards providing a novel presentation for such combination products which will overcome at least some of these problems.
Statements of Invention
The invention provides novel pharmaceutically active and stable adducts containing Clarithromycin and Ranitidine or a hydrate thereof wherein the molar ratio of Clarithromycin to Ranitidine in the adduct is at least 2:1.
The preferred H2-receptor antagonist is Ranitidine which is preferably introduced as the base hydrate.
The ratios may be integers or non-integers.
The invention also provides a process for the preparation of an adduct of the invention in which Clarithromycin and Ranitidine are reacted in an organic or aqueous solvent. Preferably the reaction temperature is from 20°C to 25°C.
Ideally, the solvent is petroleum ether.
The invention further provides the use of the adducts of the invention for the treatment of gastrointestinal disorders.
In addition, the invention provides a pharmaceutical formulation including an adduct of the invention.
Detailed description of the invention
It has surprisingly been found that Ranitidine can be bound to Clarithromycin by formation of adducts. This feature is of significance for the preparation of novel combination products, especially for the treatment of gastrointestinal disorders.
The Ranitidine can be administered simultaneously with the Clarithromycin in one unit. The ratio of Ranitidine to Clarithromycin can be readily varied, as required. The formed adducts may be readily used for final product formulations, e.g. for the manufacture of tablets or capsules. No pre-mixing of the individual components is required.
It has been observed that the Ranitidine is especially suitable to form adducts with Clarithromycin. Ranitidine may be used conveniently as the base without converting it into a pharmaceutically acceptable and stable salt prior to the formation of the adduct.
Ranitidine may be reacted with Clarithromycin to produce novel adducts which are of high stability. The adducts are antibiotically active and suitable for the treatment of gastiointestinal disorders.
Adducts prepared from Ranitidine base hydrate and Clarithromycin were found to be of particular interest. Ranitidine base hydrate is described in detail in our WO-A-99/65890 the entire contents of which are incorporated herein by reference. Such adducts can be obtained via a very simple process in high quality and quantitative yield under very mild reaction conditions.
The novel adducts may be conveniently formulated, e.g. preferably into orally administerable medicaments such as tablets or capsules. Those skilled in the art can decide which excipients, carriers, solvents, fillers, lubricants, techniques and quantities are employed in the formulation process.
The invention will be more clearly understood from the following example.
Preparation of a Clarithromvcrn-Ranitidine-[2:l] adduct
2.50 kg (3.33 mol) of Clarithromycin and 640 g (1.67 mol) of Ranitidine base hydrate are suspended in approximately 7-8 1 of a suitable solvent such as petroleum ether. The mixture is agitated preferably at room temperature for several hours. The product is filtered off, washed with some solvent and dried under vacuum, optionally at elevated temperature. A quantitative yield is typically obtained. Analytical data:
Mp.: 210.4-211.9°C.
FT-IR (KBr): v [cm 1] = 3488, 2978, 2940, 1733, 1691, 1458, 1379, 1171, 1107, 1051, 1011 (Figure 1).
Powder X-ray peaks of medium and high intensity:
Clarithromycin-Ranitidine [2:1]: 2Θ = 8.81, 9.75, 11.04, 11.68, 13.98, 15.35, 16.69, 17.06, 17.45, 18.27, 19.27, 20.04, 20.67, 22.36 (Figure 2).
Clarithromycin: 2Θ = 5.09, 6.80, 9.42, 10.38, 10.65, 12.11, 12.37, 13.99, 14.32, 15.48, 16.47, 19.11, 21.41, 23.11, 23.93 (Figure 3).
Ranitidine: 2Θ = 8.91, 16.19, 17.21, 17.74, 19.94, 22.30, 25.66, 26.09, 28.04 (Figure 4).
Antibiotic Activity
Micrococcus luteus from stock was streaked on a nutrient agar plate to confirm colony morpbiology, colour and purity. After 24 hours incubation at 37°C an isolated colony is picked and inoculated into 10 ml of nutrient broth. This is incubated overnight at 37°C and is subsequently used as the inoculum.
10 mg of each of the test compounds is weighed and dissolved in 10 ml of analar methanol in sterile 20 ml universal containers. This is then diluted with ringers buffer solution to give a concentration of 1 mg/ml.
Quantitation of activity is determined using an MIC (Mean Inhibitory Concentration) liquid tube assay. For each test substance the following concentrations are set up: 10 μg/ml, 5 μg/ml, 1 μg/ml, 0.5 μg/ml, 0J μg/ml, 0.05 μg/ml and 0.01 μg/ml. Each contained nutrient broth and 0J ml of overnight culture of Micrococcus luteus.
The tubes were incubated at 37°C and observed for growth after 24 hours and 48 hours. Growth is assessed by dense turbidity, optical density at 660 nm using a spectrophotometer or clarity. The MIC is the last concentration where growth inhibited.
The following table gives the MIC values for the compounds examined:
Compound MIC [μg/mll
Clarithromycin ≤ o.oi
Clarithromycin-Ranitidine [2:1] < 0.01 Ranitidine Base Hydrate no significant antibiotic activity
The invention is not limited to the embodiments hereinbefore described which may be varied in detail.
Claims
1. An adduct containing Clarithromycin and Ranitidine or a hydrate thereof wherein the molar ratio of Clarithromycin to Ranitidine in the adduct is at least 2:1.
2. An adduct as claimed in claim 1 wherein the Ranitidine is present in the form of Ranitidine base.
3. An adduct as claimed in claim 1 wherein the Ranitidine is present in the form of Ranitidine base hydrate.
4. An adduct substantially as hereinbefore described with reference to the examples.
5. A process for the preparation of an adduct as claimed in any preceding claim wherein Clarithromycin and Ranitidine or a hydrate thereof are reacted in an organic or aqueous solvent.
6. A process as claimed in claim 5 wherein the reaction temperature is from
20°C to 25°C.
7. A process as claimed in any of claims 5 to 6 wherein the organic solvent is petroleum ether.
8. A process for the preparation of an adduct substantially as hereinbefore described with reference to the examples.
9. An adduct containing Clarithromycin and Ranitidine or a hydrate thereof whenever prepared by a process as claimed in any of claims 5 to 8.
10. Use of an adduct containing Clarithromycin and Ranitidine or a hydrate thereof for the treatment of gastrointestinal disorders.
11. Use as claimed in claim 10 wherein the adduct is as claimed in any of claims 1 to 4 or 9.
12. A pharmaceutical formulation including an adduct containing Clarithromycin and Ranitidine or a hydrate thereof wherein the molar ratio of Clarithromycin to Ranitidine in the adduct is at least 2:1.
13. A formulation as claimed in claim 12 wherein the adduct is as claimed in any of claims 1 to 4 or 9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU36680/00A AU3668000A (en) | 1999-04-29 | 2000-04-04 | Compounds |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE990357 | 1999-04-29 | ||
| IE990357 | 1999-04-29 | ||
| IE990993 | 1999-11-29 | ||
| IE990993 | 1999-11-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2000066174A2 true WO2000066174A2 (en) | 2000-11-09 |
| WO2000066174A3 WO2000066174A3 (en) | 2001-03-15 |
Family
ID=26320246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IE2000/000041 WO2000066174A2 (en) | 1999-04-29 | 2000-04-04 | Compounds |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU3668000A (en) |
| WO (1) | WO2000066174A2 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0533281A1 (en) * | 1991-09-20 | 1993-03-24 | Glaxo Group Limited | The use of ranitidine bismuth citrate and one or more heliocobacte pylon-inhibiting antibiotics with manufacture of a medicament for treating gastrointestinal disorders |
| WO1998056357A1 (en) * | 1995-12-19 | 1998-12-17 | Abbott Laboratories | A controlled release formulation for poorly soluble basic drugs |
| WO1999065890A1 (en) * | 1998-06-17 | 1999-12-23 | Russinsky Limited | Ranitidine adduct |
-
2000
- 2000-04-04 AU AU36680/00A patent/AU3668000A/en not_active Abandoned
- 2000-04-04 WO PCT/IE2000/000041 patent/WO2000066174A2/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0533281A1 (en) * | 1991-09-20 | 1993-03-24 | Glaxo Group Limited | The use of ranitidine bismuth citrate and one or more heliocobacte pylon-inhibiting antibiotics with manufacture of a medicament for treating gastrointestinal disorders |
| WO1998056357A1 (en) * | 1995-12-19 | 1998-12-17 | Abbott Laboratories | A controlled release formulation for poorly soluble basic drugs |
| WO1999065890A1 (en) * | 1998-06-17 | 1999-12-23 | Russinsky Limited | Ranitidine adduct |
Non-Patent Citations (1)
| Title |
|---|
| FROTZ H ET AL: "Ä Ranitidine and clarithromycin for eradication of Helicobacter pylori in patients with duodenal ulcerÜ. Ranitidin und Clarithromycin zur Eradikation von Helicobacter pylori bei Patienten mit Ulcus duodeni." ARZNEIMITTEL-FORSCHUNG, (1995 FEB) 45 (2) 184-6. , XP002155014 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000066174A3 (en) | 2001-03-15 |
| IE20000248A1 (en) | 2000-11-29 |
| AU3668000A (en) | 2000-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1071331C (en) | Anti-helicobacter acyl derivatives of azolones | |
| TWI422372B (en) | Rifamycin derivatives | |
| CZ297363B6 (en) | 8-Cyano-1-cyclopropyl-6-fluoro-7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-1,4-dihydro-4-oxo-3-quinoline carboxylic acid, its use and medicaments in which the acid is comprised | |
| US6413969B1 (en) | Gatifloxacin pentahydrate | |
| FR2470134A1 (en) | NOVEL ANTIBIOTICS, THEIR PREPARATION AND THEIR USE | |
| RU2204565C2 (en) | Bismuth salts of antibiotics of group moenomycin, method of their preparing, their using and medicinal agents containing such salts | |
| CA2201097A1 (en) | Anti-tumor agents | |
| EP0787494B1 (en) | Use of rifamycin derivatives for the manufacture of a medicament for the treatment of diseases caused by infections of helicobacter pylori | |
| WO2000066174A2 (en) | Compounds | |
| IE83226B1 (en) | An adduct containing clarithromycin and ranitidine | |
| US6599885B2 (en) | Derivatives of erythromycin, clarithromycin, roxithromycin or azithromycin with antibiotic and mucolytic activity | |
| US20170355671A1 (en) | Peripherally substituted monocyclic beta-lactams | |
| WO1995028929A1 (en) | Aminoline-n-oxide antimicrobials for use against h. pylori infections | |
| US6548485B2 (en) | Stable antitumor drug | |
| BG99035A (en) | Crystals of antimicrobial compound and method for their preparation | |
| KR20000016544A (en) | Improved process for preparing potassium clavulanate | |
| AU626576B2 (en) | Crystalline (5r,6s)-2-carbamoyloxymethyl-6-{(1r)- hydroxyethyl}-2-penem-carboxylic acid and its pharmaceutical formulation | |
| JP3949750B2 (en) | N, N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine dimaleate | |
| EP0369503B1 (en) | Method for the control of pneumocystis carinii | |
| KR100274736B1 (en) | Polymorphs of the prodrug 6-n-(l-ala-l-ala)-trovafloxacin | |
| KR860000450B1 (en) | Method for preparing a water-soluble complex of α-6-deoxy-5-hydroxy tetracycline and sodium tetrametaphosphate | |
| US20020004595A1 (en) | Process for preparing potassium clavulanate | |
| JP4159130B2 (en) | Therapeutic agent for diseases caused by Helicobacter infection | |
| US4607024A (en) | Epoxypropylphosphonate salt of jesamycin and pharmaceutical composition containing same | |
| DK146778B (en) | ANALOGY PROCEDURE FOR PREPARING SEMI-SYNTHETIC OLEANDOMYCIN COMPOUNDS OR NOT TOXIC ACID ADDITION SALTS THEREOF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase in: |
Ref country code: JP |